Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer

被引：15

作者：

Sonpavde, Guru ^{[1
,2
]}

Chi, Kim N. ^{[3
]}

Powles, Thomas ^{[4
]}

Sweeney, Christopher J. ^{[5
]}

Hahn, Noah ^{[5
]}

Hutson, Thomas E. ^{[1
]}

Galsky, Matthew D. ^{[1
]}

Berry, William R. ^{[1
]}

Kadmon, Dov ^{[2
]}

机构：

[1] US Oncol Res, Genitourinary Oncol Program, Houston, TX USA

[2] Baylor Coll Med, Scott Dept Urol, Houston, TX USA

[3] British Columbia Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada

[4] London Hosp, Dept Oncol, London, England

[5] Indiana Univ, Med Ctr, Sect Med Oncol, Dept Med, Indianapolis, IN USA

来源：

CANCER | 2007年 / 110卷 / 12期

关键词：

multidisciplinary approach; neoadjuvant therapy; prostate cancer; hormonal therapy; chemotherapy; biologic therapy;

D O I：

10.1002/cncr.23085

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The results of this assessment of the literature indicated that neoadjuvant therapy followed by prostatectomy may improve long-term outcomes for patients with high-risk localized disease. In addition, this approach provides a paradigm for evaluating the activity and mechanism of action of new agents as correlative Studies are facilitated by the availability of tumor tissue before and after therapy. The authors determined that a multidisciplinary approach involving oncologists, urologists, and pathologists is critical to the success of this model. Recent and ongoing studies of neoadjuvant therapy followed by prostatectomy were reviewed.

引用

页码：2628 / 2639

页数：12

共 57 条

[1] Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial [J].

Aus, G ;

Abrahamsson, PA ;

Ahlgren, G ;

Hugosson, J ;

Lundberg, S ;

Schain, M ;

Schelin, S ;

Pedersen, K .

BJU INTERNATIONAL, 2002, 90 (06) :561-566

[2] Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma [J].

Bazinet, M ;

Zheng, W ;

Begin, LR ;

Aprikian, AG ;

Karakiewicz, PI ;

Elhilali, MM .

UROLOGY, 1997, 49 (05) :721-725

[3] Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial and basic biology [J].

Belldegrun, A ;

Tso, CL ;

Zisman, A ;

Naitoh, J ;

Said, J ;

Pantuck, AJ ;

Hinkel, A ;

de Kernion, J ;

Figlin, R .

HUMAN GENE THERAPY, 2001, 12 (08) :883-892

[4] Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial [J].

Bolla, M ;

Collette, L ;

Blank, L ;

Warde, P ;

Dubois, JB ;

Mirimanoff, RO ;

Storme, G ;

Bernier, J ;

Kuten, A ;

Sternberg, C ;

Mattelaer, J ;

Torecilla, JL ;

Pfeffer, JR ;

Cutajar, CL ;

Zurlo, A ;

Pierart, M .

LANCET, 2002, 360 (9327) :103-108

[5] Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer [J].

Carducci, Michael A. ;

Musib, Luna ;

Kies, Merrill S. ;

Pili, Roberto ;

Truong, Mylene ;

Brahmer, Julie R. ;

Cole, Patricia ;

Sullivan, Rana ;

Riddle, Jeanne ;

Schmidt, Jill ;

Enas, Nathan ;

Sinha, Vikram ;

Thornton, Donald E. ;

Herbst, Roy S. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (25) :4092-4099

[6] A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer [J].

Chi, KN ;

Eisenhauer, E ;

Fazli, L ;

Jones, EC ;

Goldenberg, SL ;

Powers, J ;

Tu, DS ;

Gleave, ME .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1287-1296

[7] Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer [J].

Clark, PE ;

Peereboom, DM ;

Dreicher, R ;

Levin, HS ;

Clark, SB ;

Klein, EA .

UROLOGY, 2001, 57 (02) :281-285

[8] Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial [J].

Demetri, George D. ;

van Oosterom, Allan T. ;

Garrett, Christopher R. ;

Blackstein, Martin E. ;

Shah, Manisha H. ;

Verweij, Jaap ;

McArthur, Grant ;

Judson, Ian R. ;

Heinrich, Michael C. ;

Morgan, Jeffrey A. ;

Desai, Jayesh ;

D Fletcher, Christopher ;

George, Suzanne ;

Bello, Carlo L. ;

Huang, Xin ;

Baum, Charles M. ;

Casali, Paolo G. .

LANCET, 2006, 368 (9544) :1329-1338

[9] Phase II trial of GM-CSF plus thalidomide in patients with androgen-independent metastatic prostate cancer [J].

Dreicer, R ;

Klein, EA ;

Elson, P ;

Peereboom, D ;

Byzova, T ;

Plow, EF .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2005, 23 (02) :82-86

[10] Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer [J].

Dreicer, R ;

Magi-Galluzzi, C ;

Zhou, M ;

Rothaermel, J ;

Reuther, A ;

Ulchaker, J ;

Zippe, C ;

Fergany, A ;

Klein, EA .

UROLOGY, 2004, 63 (06) :1138-1142

← 1 2 3 4 5 6 →